Thorac Cardiovasc Surg 2019; 67(07): 554-556
DOI: 10.1055/s-0039-1692651
Short Communication
Georg Thieme Verlag KG Stuttgart · New York

Continuous Beta-Blocker Therapy Delays Structural Deterioration after Bioprosthetic Mitral Valve Replacement

Wenrui Ma*
1   Department of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai, China
2   Zhongshan Hospital Fudan University, Shanghai, China
,
Yan Tan*
3   Department of Intensive Care Unit, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China
,
Qiuxia Shi
4   Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Beijing, China
,
Zhiwei Xu
1   Department of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai, China
5   Department of Cardiac Surgery, Huai’an First People’s Hospital, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China
› Author Affiliations
Further Information

Publication History

21 March 2019

06 May 2019

Publication Date:
28 June 2019 (online)

Abstract

The impact of continuous beta-blocker (BB) therapy on structural valve deterioration (SVD) after bioprosthetic mitral replacement was investigated. From 2000 to 2005, 138 such patients were propensity score matched in a 1:1 fashion (continuous BB therapy after surgery, n = 69; without BB therapy, n = 69). Median follow-up was 12.3 years. Cardiac mortality was comparable between patients with and without BB therapy (p = 0.13), while the 10-year freedom from SVD was significantly higher in patients with BB therapy (92.4 vs. 76.3%, p = 0.001). In conclusion, continuous BB therapy may be considered in patients after bioprosthetic mitral valve replacement to delay SVD and improve prosthetic durability.

* Drs Wenrui Ma and Yan Tan are designated as the joint first authors and have made equal contributions to the manuscript.


 
  • References

  • 1 Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol 2010; 55 (22) 2413-2426
  • 2 Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation 2009; 119 (07) 1034-1048
  • 3 Schoen FJ, Fernandez J, Gonzalez-Lavin L, Cernaianu A. Causes of failure and pathologic findings in surgically removed Ionescu-Shiley standard bovine pericardial heart valve bioprostheses: emphasis on progressive structural deterioration. Circulation 1987; 76 (03) 618-627
  • 4 Chan AY, McAlister FA, Norris CM, Johnstone D, Bakal JA, Ross DB. ; Alberta Provincial Program for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Effect of beta-blocker use on outcomes after discharge in patients who underwent cardiac surgery. J Thorac Cardiovasc Surg 2010; 140 (01) 182-187 , 187.e1
  • 5 Zoghbi WA, Chambers JB, Dumesnil JG. , et al; American Society of Echocardiography's Guidelines and Standards Committee; Task Force on Prosthetic Valves; American College of Cardiology Cardiovascular Imaging Committee; Cardiac Imaging Committee of the American Heart Association; European Association of Echocardiography; European Society of Cardiology; Japanese Society of Echocardiography; Canadian Society of Echocardiography; American College of Cardiology Foundation; American Heart Association; European Association of Echocardiography; European Society of Cardiology; Japanese Society of Echocardiography; Canadian Society of Echocardiography. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009; 22 (09) 975-1014 , quiz 1082–1084
  • 6 Salaun E, Mahjoub H, Girerd N. , et al. Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement. Circulation 2018; 138 (10) 971-985
  • 7 Valfrè C, Ius P, Minniti G. , et al. The fate of Hancock II porcine valve recipients 25 years after implant. Eur J Cardiothorac Surg 2010; 38 (02) 141-146
  • 8 Rizzoli G, Bottio T, Thiene G, Toscano G, Casarotto D. Long-term durability of the Hancock II porcine bioprosthesis. J Thorac Cardiovasc Surg 2003; 126 (01) 66-74
  • 9 Borger MA, Ivanov J, Armstrong S, Christie-Hrybinsky D, Feindel CM, David TE. Twenty-year results of the Hancock II bioprosthesis. J Heart Valve Dis 2006; 15 (01) 49-55 , discussion 55–56
  • 10 Grunkemeier GL, Furnary AP, Wu Y, Wang L, Starr A. Durability of pericardial versus porcine bioprosthetic heart valves. J Thorac Cardiovasc Surg 2012; 144 (06) 1381-1386